Mereo BioPharma Group plc Mereo CEO appointed NED of Elanco Animal Health (6597S)
13 March 2019 - 10:00PM
UK Regulatory
TIDMMPH
RNS Number : 6597S
Mereo BioPharma Group plc
13 March 2019
Mereo BioPharma Group plc
("Mereo")
Mereo BioPharma announces the appointment of its CEO, Denise
Scots-Knight, as a non-executive director to the Board of Elanco
Animal Health Inc.
London, 13 March 2019 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
diseases, announces that in accordance with AIM Rule 17, Dr. Denise
Scots-Knight, Chief Executive Officer of Mereo, has been appointed
as a member of the Board of Directors at Elanco Animal Health
Incorporated (NYSE: ELAN) with effect from 11 March 2019.
Elanco develops products and knowledge services to prevent and
treat disease in food animals and pets in more than 90 countries.
The Company has approximately 5,800 employees. The Board of
Directors was initially established in September 2018 when Elanco
became a fully independent public company, following its separation
from Eli Lilly and Company (NYSE:LLY).
For Further Enquiries:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser
and Joint Broker to Mereo) +44 (0)20 7894 7000
Phil Davies
Will Goode
RBC Capital Markets (Joint Broker to Mereo) +44 (0)20 7653 4000
Rupert Walford
Jamil Miah
FTI Consulting (Public Relations Adviser to
Mereo)
Simon Conway +44 (0)20 3727 1000
Brett Pollard
Burns McClellan (US Public Relations Adviser
to Mereo) +1 212 213 0006
Lisa Burns
Jill Steier
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialisation of innovative therapeutics that aim to
improve outcomes for patients with rare diseases. Mereo's strategy
is to selectively acquire product candidates that have already
received significant investment from pharmaceutical companies and
that have substantial preclinical, clinical and manufacturing data
packages. In December 2018, Mereo announced the proposed
combination of Mereo and OncoMed Pharmaceuticals, with the
transaction expected to close in the second quarter of 2019. Each
of Mereo's four product candidates has previously generated
positive clinical data for Mereo's target indication or in a
related indication. Since inception Mereo has commenced large,
randomised, placebo-controlled Phase 2 clinical trials for all four
of the product candidates:
-- BPS-804 for osteogenesis imperfecta (OI). Mereo recently
announced completion of enrolment with 112 adult patients in a
Phase 2b dose ranging study with some initial data at the top dose
expected in the Q2 2019 and top-line dose ranging data in late
2019. A pediatric Phase 3 study design has also been approved by
the EMA. BPS-804 has orphan designation in the US and EU and has
been accepted into the PRIME and Adaptive Pathways in EU;
-- MPH-966 for alpha-1 antitrypsin deficiency (AATD). Mereo
recently announced first patient in a Phase 2 dose ranging study in
the US with data expected in late 2019;
-- BCT-197 for acute exacerbations of COPD (AECOPD). Mereo
announced positive Phase 2 data in May 2018; and
-- BGS-649 for hypogonadotropic hypogonadism (HH). Mereo
announced positive top-line Phase 2b data in March 2018 and
positive results from the Phase 2b safety extension study in
December 2018.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBRGDXLSBBGCD
(END) Dow Jones Newswires
March 13, 2019 07:00 ET (11:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024